October 2, 2023
- August 24, 2023 - Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required). See NOFO PAR-23-274.
National Institute on Aging (NIA)
This Notice informs potential applicants that the Key Dates information listed in Notice of Funding Opportunity (NOFO) PAR-23-274, “Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)” has changed.
The following section under Part 1. Overview Information of PAR-23-274 has been modified:
Key Dates
The first three rows of the table currently reads:
Application Due Dates | Review and Award Cycles | ||||
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/ Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| February 21, 2024 | March 21, 2024 | Not Applicable | June 2024 | August 2024 | September 2024 |
The third row of the table was revised to read (changes shown in bold italics):
Application Due Dates | Review and Award Cycles | ||||
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/ Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| February 21, 2024 | March 21, 2024 | Not Applicable | June 2024 | October 2024 | November 2024 |
All other aspects of this NOFO remain unchanged.
Scientific/Research Contact(s)
Akanni Clarke
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: [email protected]
Laurie Ryan
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: [email protected]
and Human Services (HHS)
